U.S. Senate Majority Leader Charles Schumer and Congressman Paul Tonko recently announced $984,000 in funding to support Rensselaer Polytechnic Institute’s request for enhancing its state-of-the art Nuclear Magnetic Resonance (NMR) facility focused on innovative research related to the treatment of Alzheimer’s, drug discovery, diabetes, osteoporosis, and a broad range of other diseases and viruses.

The facility will be based within Rensselaer’s Center for Biotechnology and Interdisciplinary Studies (CBIS) that conducts multi- and interdisciplinary research at the interface of engineering and life sciences. “While supporting transformative research, the NMR facility will provide new opportunities for student training, building the workforce of the future, and will serve as hub for Capital Region biotech companies to conduct research facilitating new drug discoveries, products, treatments, and therapies,” said Deepak Vashishth, Director of CBIS.

“On behalf of Rensselaer, I want to thank Senate Majority Leader Schumer for securing this funding for the enhancement of our Nuclear Magnetic Resonance facility,” said Dr. Robert Hull, Acting Vice President for Research at Rensselaer. “Thanks to his efforts, Rensselaer will bring state-of-the-art biotech equipment to New York’s Capital Region that will be used for research, industry collaborations, and to train the next generation of biotech students and workers.”